Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort

Key Points

• Claudin 18.2 expression correlates with clinical outcomes in gastroesophageal adenocarcinoma, indicating its potential as a prognostic biomarker.
• The study highlights a substantial overlap of claudin 18.2 with other established biomarkers in this cancer type, underlining its importance.
• Observational analysis across a European cohort demonstrates the association between claudin 18.2 levels and patient prognosis.
• These findings support the exploration of new treatment options targeting claudin 18.2, potentially enhancing patient management strategies.